List view / Grid view
8 January 2015 | By Oxford Global Conferences
Oxford Global Conferences were proud to present the Drug Discovery USA Congress this October in Boston, USA...
8 January 2015 | By SciFluor Life Sciences
SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,916,133 with claims covering the novel compound SF0034...
8 January 2015 | By Advanced Accelerator Applications S.A.
Advanced Accelerator Applications S.A. announced that it has acquired the remaining 49.9% of Atreus Pharmaceuticals Corporation, a development-stage biopharmaceutical company headquartered in Ottawa, Canada...
8 January 2015 | By MSD
NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...
6 January 2015 | By TxCell
TxCell SA (FR0010127662 – TXCL) announces that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis...
6 January 2015 | By The Institute of Cancer Research
An experimental cancer drug may block an important driver for the survival, growth and spread of cancer cells...
5 January 2015 | By Pfizer
Acquisition provides Pfizer with a preclinical CMV vaccine candidate...
17 December 2014 | By MRC Technology
Structure-based drug discovery platform targets challenging GPCRs linked to human disease...
17 December 2014 | By Midatech Pharma
Midatech Pharma, a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs, is pleased to announce that a consortium of academic and industry groups including Midatech has been awarded a €3.8 million European Union grant...
16 December 2014 | By Curie-Cancer
Clinical trials are scheduled for 2015 to explore the value of the candidate drug 3C23K in relapsing ovarian cancer...
16 December 2014 | By Kymab
Kymab, a monoclonal antibody biopharmaceutical company, founded on research from the Wellcome Trust Sanger Institute announces that it has been awarded a grant from the Wellcome Trust to lead a consortium developing new treatments in the fight against Ebola...
15 December 2014 | By The Institute of Cancer Research, London, and Cancer Research UK Manchester Institute
A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports...
12 December 2014 | By Frost & Sullivan
Convergence of immunodiagnostic and molecular tests will help meet demand in developed countries, says Frost & Sullivan...
10 December 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis (apixaban) by 4-factor prothrombin complex concentrates (PCCs) in healthy subjects...
10 December 2014 | By ZoBio and Domainex
ZoBio (Leiden, The Netherlands) and Domainex Ltd. (Cambridge, UK) announce a collaboration with FORMA Therapeutics (Watertown, MA, USA) to provide NMR-based structural biology services for a substantial panel of FORMA drug targets...
